#Longevity
Aging biology, cellular senescence, peptide-class interventions discussed in the longevity field.
Semaglutide Plus Niacin for Lung Fibrosis
A rat study paired semaglutide with niacin against lung scarring, targeting the NAD+/SIRT1-FOXO3a-Nrf2 pathway. Here is what it does and does not show.
GLP-1 drugs at longevity clinics
Longevity and aesthetic clinics prescribe semaglutide and tirzepatide off-label. Here is what the labels cover, and where the ageing evidence stops.
Browse other coverage
Latest from the blog
Adolescent GLP-1 Review: Evidence Gaps
A 2026 review finds short-term benefits from adolescent GLP-1 therapy but major gaps around growth, puberty, cognition and lifelong effects.
AGGF1 and the diabetic kidney barrier
A 2026 laboratory study links AGGF1 with glomerular barrier leakage and semaglutide-related junction changes in diabetic mice.
GLP-1s in Foot and Ankle Surgery
A 2026 review found neutral or potentially better outcomes with perioperative GLP-1 use, but all three comparative studies were retrospective.
Obesity and Facial Plastic Surgery
A 2026 review links obesity, weight loss and injectable drugs to facial-surgery questions but reports no direct patient outcomes.
PYY(3-36) and semaglutide in rat MASLD
A 48-rat MASLD study found stronger liver and mitochondrial changes with PYY(3-36) plus semaglutide, but it provides no human efficacy evidence.
Retatrutide and cognition in diabetic rats
A rat study linked retatrutide with better maze performance and lower brain inflammation, but it provides no evidence of cognitive benefit in people.